Development

Dosage forms are being shaped by numerous factors, with patient-centricity continuing to be an important driver of decisions in development.

Twin-screw granulation process insight is growing as researchers employ new analytical technologies and investigate new ways to use the equipment.

Sustainability advances are being made, but more investment is needed.

In this episode of Drug Digest, Pharmaceutical Technology’s European/Senior Editor, Felicity Thomas, discusses small-molecule APIs, excipients, and formulation advances, including a discussion about novel approaches and solutions to pediatric formulations and taste-masking, a rundown of the fundamental stages of gaining a certificate of suitability for APIs, and a deliberation on the biggest trends impacting the industry and key sessions to visit while at CPHI, with several key industry experts.

BenevolentAI will leverage its suite of AI chemistry design tools in combination with its fully equipped wet lab facility in Cambridge, UK, to deliver small molecule drug development candidates into the Merck pipeline, according to the press release.

Under the collaboration, Orionis will receive $47 million upfront to leverage its Allo-Glue platform to discover small-molecule monovalent glues.

Maik Jornitz, Principal Consultant, BioProcess Resources LLC, discusses the definition of patient safety and how to implement new technologies into upgraded facilities.

Webinar Date/Time: Wed, Oct 4, 2023 - 11:00 am EDT | 4:00 pm GMT | 5:00 pm CEST | 8:00 am PDT

Webinar Date/Time: Wed, Oct 11, 2023 - 11:00 am EDT | 4:00 pm GMT | 5:00 pm CEST | 8:00 am PDT

The EMA’s Committee for Medicinal Products for Human Use has given a positive opinion on Sandoz’ biosimilar trastuzumab for breast and gastric cancer.

Recipharm will provide analytical and process development capabilities to support toxicology studies, in addition to GLP manufacturing of lipid nanoparticles to capture the active pharmaceutical ingredient, an antigen peptide.

The agreement states that Orbit will implement its bead-based peptide display engine to discover peptide leads specific to targets related to specific tumors.

Advanced analytical tools generate more data in today’s labs than ever before.

Webinar Date/Time: Wed, Oct 11, 2023 11:00 AM EDT

Excipients should be treated equally when it comes to quality management, risk assessment, and testing.

Coprocessed excipients save time and cost while improving performance in a widening array of dosage forms.

Pharma's ability to continually reinvent itself will be critical in growing future business operations.

Extensive research on various gene editing techniques could inform the future of mRNA therapies.

Twist Bioscience is a synthetic biology and genomics company that has developed a DNA synthesis platform to industrialize the engineering of biology, which is a new method of this process by “writing” DNA on a silicon chip.

Webinar Date/Time: Thursday, September 21, 2023 at 11am ET | 10am CT | 8am PT | 4 pm BST

Webinar Date/Time: Wed, Sep 20, 2023 11:00 AM EDT

The formulation will be used to mitigate emerging infectious diseases and public health emergencies.

FDA has halted enrollment in clinical studies for Gilead Sciences’ magrolimab, a biologic treatment in development for acute myeloid leukemia.

With this agreement, Chiesi Global Rare Diseases will co-develop drug delivery systems with Aliada Therapeutics for large-molecule therapeutics that can cross the blood-brain barrier.

A major grant from the Bill & Melinda Gates Foundation will bolster efforts to fight the global HIV/AIDS epidemic.

HitGen has entered into a research service agreement with Nested Therapeutics for use of HitGen’s DNA-encoded library for drug discovery.

Webinar Date/Time: Thu, Sep 28, 2023 11:00 AM EDT

The biggest hurdle is developing palatable formulations that are efficacious and patient friendly.

An intelligent drug development paradigm can enable small pharma to implement an effective early drug development approach.

mRNA may be a modality whose chief advances are yet to come.